REPOTRECTINIB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H18FN5O2
Molecular Weight	355.3662
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H]1CNC(=O)C2=C3N=C(N[C@H](C)C4=C(O1)C=CC(F)=C4)C=CN3N=C2

InChI

InChIKey=FIKPXCOQUIZNHB-WDEREUQCSA-N

InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C18H18FN5O2
Molecular Weight	355.3662
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30093503 | https://www.cancertherapyadvisor.com/home/cancer-topics/lung-cancer/tpx-0005-granted-orphan-drug-designation-for-non-small-cell-lung-cancer/

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor. It represents an effective therapeutic option for patients with ROS1-, NTRK1-3-, or ALK-rearranged malignancies who have progressed on earlier-generation tyrosine kinase inhibitors. In June 2017, The US Food and Drug Administration (FDA) granted orphan drug designation to this drug for the treatment of Non–small cell lung adenocarcinoma with an ALK, ROS1, or NTRK mutation.

Approval Year

Targets

Primary Target	Pharmacology	Potency
Proto-oncogene tyrosine-protein kinase ROS 5 Target ID: P08922 Gene ID: 6098.0 Gene Symbol: ROS1 Target Organism: Homo sapiens (Human) Sources: DOI: 10.1158/1535-7163 retrieved from http://mct.aacrjournals.org/content/17/1_Supplement/B185	Inhibitor 8504	0.076 nM [IC50]
ALK tyrosine kinase receptor 24 Target ID: Q9UM73 Gene ID: 238.0 Gene Symbol: ALK Target Organism: Homo sapiens (Human) Sources: DOI: 10.1158/1538-7445 retrieved from http://cancerres.aacrjournals.org/content/76/14_Supplement/2132	Inhibitor 8504	1.01 nM [IC50]
Proto-oncogene tyrosine-protein kinase Src 8 Target ID: P12931 Gene ID: 6714.0 Gene Symbol: SRC Target Organism: Homo sapiens (Human) Sources: DOI: 10.1158/1538-7445 retrieved from http://cancerres.aacrjournals.org/content/76/14_Supplement/2132	Inhibitor 8504	5.3 nM [IC50]
Neurotrophic tyrosine kinase receptor 2 Target ID: CHEMBL3559684 Sources: doi:10.1158/1538-7445.AM2017-3168 retrieved from http://cancerres.aacrjournals.org/content/77/13_Supplement/3168	Inhibitor 8504

C_max

Value	Dose	Co-administered	Analyte	Population
713 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf	160 mg 2 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		REPOTRECTINIB plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
7210 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf	160 mg 2 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		REPOTRECTINIB plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
60.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf	160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered:		REPOTRECTINIB plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% EXPERIMENT https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00712	single, oral		REPOTRECTINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.6% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf	160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered:		REPOTRECTINIB plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Substance Class	Chemical Created by `admin` on `Tue Apr 01 17:24:03 GMT 2025` Edited by `admin` on `Tue Apr 01 17:24:03 GMT 2025`
Record UNII	08O3FQ4UNP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TPX-0005

Preferred Name

English

REPOTRECTINIB

Official Name

English

repotrectinib [INN]

Common Name

English

(3R,6S,)-45-Fluoro-3,6-dimethyl-5-oxa-2,8-diaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-4(1,2)-benzenanonaphan-9-one

Systematic Name

English

Repotrectinib [WHO-DD]

Common Name

English

1,15-ETHENO-1H-PYRAZOLO(4,3-F)(1,4,8,10)BENZOXATRIAZACYCLOTRIDECIN-4(5H)-ONE, 11-FLUORO-6,7,13,14-TETRAHYDRO-7,13-DIMETHYL-, (7S,13R)-

Systematic Name

English

REPOTRECTINIB [USAN]

Common Name

English

AUGTYRO

Brand Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

573517